Aditxt, Inc.

ADTX Healthcare Biotechnology

Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024. In the quarter to March 2026, revenue grew 1,120.0%, EPS grew 99.6% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.00 0.00 NaN
Market cap
$4.4M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−22.29
Beneish M
n/a
Dividend safety
n/a
Older periods Jun '25 Sep '25 Dec '25 Mar '26
Piotroski F-Score

+8 more TTM periods

4 — — —
ROE
(338.55%) 1,915.52% (1,708.64%) 549.59%
ROA
(101.67%) (202.88%) (177.15%) (236.38%)
ROIC
(118.41%) 0.00% (1,619.88%) 0.00%
Return on Tangible Assets
165.67% 223.57% 573.29% 456.62%
Average Days of Receivables
1,197.56 11,642.88 0.00 306.29
Free Cash Flow per Share
(226,094.00) (112,948.50) (18,365.36) (920.15)
Free Cash Flow
(22.61) (22.59) (25.71) (18.59)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026